1/ I keep thinking about one exchange @ethanjweiss and I had on the #CholesterolScience broadcast... more so than any I've had in any prior interview before. I've cued it to the right timecode here:
2/ In this moment, we're talking about the finding of the 4S trial that @erreyedoc was mentioning (linked here). And in particular, we're talking about those with high LDL, high HDL, and low TG in the existing statin trial data would show a low risk group.
https://twitter.com/erreyedoc/status/1162070100037574656?s=20
3/ I point out why I'm genuinely stunned this "positive" triad (and certainly one I'm focused on) hasn't garnered the attention of the medical community. Why wasn't there a push right there to better identify and understand if this specific group was being served by Rx treatment?
4/ @ethanjweiss correctly points out that the industry has no reason to shrink its market, which is understandable. That's not where my expectations are -- it's with the scientific community itself. We already had lots of studies on atherogenic dyslipidemia (⬇️HDL ⬆️TG ⬆️SDLDL)..
5/ Why wouldn't we have taken great interest on "reverse atherogenic dyslipidemia" where LDL is high, particularly in the wake of this post hoc study with 4S? To the best of my knowledge, we haven't seen another one since with any other drug trials.
6/ I hope @ethanjweiss is right in that data collection will require full transparency moving forward. I'm certainly interested in how all this applies to the triad of (⬆️LDL+⬆️HDL+⬇️TG).
• • •
Missing some Tweet in this thread? You can try to
force a refresh
